Immunovaccine to Host Investor Event on April 10, 2018 in New York City
March 13 2018 - 4:05PM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, announced today that it will host an
R&D Update and Investor Event for the investment community on
Tuesday, April 10, 2018 in New York City.
The event will feature an overview of Immunovaccine’s novel
approach to targeted T cell therapy. Presentations by outside
experts and Immunovaccine management will highlight the scientific
background and key opinion leaders’ (KOL) perspectives on the
company’s novel mechanism of action and its clinical applications
and potential benefits.
Details for the event are as follows:
Date: Tuesday, April 10, 2018
Time: 12:00 p.m. – 2:00 p.m. ET
(registration to begin at 11:45 a.m. ET)
Location: New York, NY
The agenda will include:
IntroductionFred Ors, Chief Executive Officer,
Immunovaccine
Defining a New Approach to Targeted T Cell
TherapyMarianne Stanford, PhD, Vice President, Research,
Immunovaccine
Elucidating a Unique Mechanism of Action Using In Vivo
MRI TrackingKim Brewer, PhD, Assistant Professor
Department of Diagnostic Radiology, Department of Physics &
Atmospheric Science, Department of Microbiology & Immunology,
Dalhousie University, Halifax, Nova Scotia, Canada
Testing Various Immune Modulators for
Neoepitope-mediated Cancer
ImmunotherapyPramod K. Srivastava, PhD, MD,
Professor of Medicine and Immunology, Eversource Energy Chair in
Experimental Oncology, Director, Neag Comprehensive Cancer Center,
University of Connecticut School of Medicine, Farmington, CT
T Cell Therapies for Cancer in Clinical Practice: Are We
on Target? Oliver Dorigo, MD, PhD, Director and Associate
Professor, Stanford Gynecologic Oncology, Director Mary Lake
Polan Laboratory for Gynecologic Cancer Research, and Director
Clinical Research Group for Gynecologic Cancer Trials, Stanford
University Medical Center, Stanford, CA
If you are a member of the investment community and would like
to attend, please send an email to tracy.sebastian@westwicke.com to
receive additional information.
A live broadcast of the event will be made available on the
Investors section of the Immunovaccine website at
http://ir.imvaccine.com. More information about how to access the
webcast will be available closer to the event.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company
dedicated to making immunotherapy more effective, more broadly
applicable, and more widely available to people facing cancer and
infectious diseases. Immunovaccine develops T cell activating
cancer immunotherapies and infectious disease vaccines based on
DepoVax™, the Company’s patented platform that provides controlled
and prolonged exposure of antigens and adjuvant to the immune
system. Immunovaccine has advanced two T cell activation therapies
for cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Company assessing lead
cancer therapy, DPX-Survivac, as a combination therapy in ovarian
cancer. The Company is also exploring additional applications of
DepoVax™, including DPX-RSV, an innovative vaccine candidate for
respiratory syncytial virus (RSV), which has recently completed a
Phase 1 clinical trial. Immunovaccine also has ongoing clinical
projects to assess the potential of DepoVax™ to address malaria and
the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown Inc. T:
(312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819
E: Plabbe@imvaccine.com
Patti Bank, Managing Director, Westwicke Partners O: (415)
513-1284 T: (415) 515-4572 E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024